Resistant scions (to HLB) produced via gene editing could reach growers sooner than transgenic varieties (HMO), Rogers said, because less government approval is needed to launch commercial production of crops developed with gene editing. Unlike transgenic processes, gene editing does not involve the transfer of genes from one organism to another. Instead, this technology “shuts off” genes that would otherwise render a citrus tree vulnerable to disease.
Taken from Michael Rogers Citrus Research & Education Center